ViQi and Agilent sign a co-marketing agreement to promote AI-based automated imaging assays

Using high-resolution images and AI-based technology to measure morphological changes in cells earlier than standard assays

SANTA BARBARA, Calif., Feb. 13, 2025 /PRNewswire-PRWeb/ -- ViQi Inc. (www.viqiai.com) and Agilent Technologies today announced a co-marketing agreement to promote imaging assays utilizing high-resolution images and AI/ML technology. Together, these companies can offer a complete solution for automating routine assays commonly used in virus research, vaccine and antiviral discovery, and analytical development in support of the manufacturing of biologics.

This agreement showcases the capabilities of the Agilent BioTek Cytation cell imaging multimode readers and the range of possibilities for using AI-based data analysis to identify cellular morphological changes leveraging ViQi's predictive AI technology. This agreement will drive high-throughput (HTP) through automation, improved precision, and reduced costs compared to the current standard manual assays. The time and cost savings will enable labs and manufacturing facilities that adopt automated assays to focus on other yet-unsolved challenges.

"ViQi's customers need access to a high-resolution and fast imager to run our AI-based assays, including our flagship assay, AVIAtm," said Kathy Yeung, ViQi's CEO. "The line of Agilent BioTek Cytations are an excellent choice for this. Through ViQi and Agilent's shared values in finding the best solutions for the labs we serve, we realize strong alignment in bringing reliable automated imaging assays to the market."

"The coordination between Agilent and ViQi will accelerate access, implementation, and adoption of automated imaging assays that leverage advanced AI/ML analysis capabilities," said Joe Clayton, Director of Applications and Technical Marketing in Agilent's Cell Analysis Division. "Agilent and ViQi can offer coordinated support to our academic and industry partners, making this agreement beneficial for all of our customers."

The agreement will initially focus on organizations working with vaccines and antiviral research, with an emphasis on AVIA utilizing images from any of the Cytation instruments. As the alliance develops, the companies will explore opportunities with other assays that extend beyond measuring viral infectivity.

A new Application Note developed by ViQi and Agilent is now available.

• Quantification of Viral Infections Using AI/ML Analysis with Brightfield Imaging ? A rapid viral infectivity assay using AVIAtm and the Agilent BioTek Cytation cell imaging multimode reader dramatically accelerates results, reduces costs, and increases precision [App Note on ViQi's website]

About ViQi

ViQi, a pioneering California-based image analysis company, unlocks the power of artificial intelligence (AI) and cloud-based software through the development of novel solutions that automate cell and tissue-based assays, transforming subjective analysis into objective, quantifiable results. We empower laboratories by making image processing and data management not only accessible but also efficient, ultimately accelerating breakthroughs in critical areas like virology research, drug discovery, and gene therapy.

ViQi's flagship innovation is the Automated Viral Infectivity Assay (AVIAtm). AVIA utilizes AI to automatically quantify viral particles even before they become visible to the human eye. This translates into a faster and more accurate assessment of viral activity, leading to significant advancements in vaccine development and infectious disease research.

Media Contact

To learn more contact the ViQi team at [email protected].

Media Contact

Heather Lorenz, ViQi, Inc., 1 8056996081, [email protected], ViQi, Inc.

SOURCE ViQi, Inc.